Caribou Biosciences, Inc. CRBU
At closeNov 3, 2026, 6:40 PM EST
After hours · Nov 3, 6:40 PM ET
- YTD
- -71.11%
- 1 year
- -81.09%
- Market cap
- 49.25M
- Revenue (ttm)
- 11.47M
- EPS (ttm)
- -1.08
- Shares out
- 90.55M
- Forward P/E
- -0.90
- YTD return
- -71.11%
- 1-year return
- -81.09%
- Volume
- 1.38M
- Avg volume
- 2.62M
- Open
- 0.427
- Previous close
- 0.4399
- Day's range
- 0.415 – 0.4646
- 52-week range
- 0.423 – 2.43
- Beta
- 2.26
- Price target
- 12.50 (+2620.9%)
- Earnings date
- Aug 6, 2024
2Y -1.8806 (-80.37%)
Key statistics
- Enterprise value
- -38.54M
- PEG ratio
- 0.00
- Price / sales
- 14.13
- Price / book
- 0.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -91.40%
- Free cash flow
- -78.73M
- Total cash
- 228.18M
- Total debt
- 26.64M
- Return on equity
- -43.60%
- Short % of float
- 9.97%
- 50-day average
- 2.08
- 200-day average
- 2.67
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 12.50
- Target (high)
- 26.00
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.41804.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.44 | -0.38 | +0.06 | +13.64% |
| Aug 6, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.45 | -0.42 | +0.03 | +6.67% |
| May 7, 2024 | Mar 1, 2024 | -0.39 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.39 | -0.46 | -0.07 | -17.95% |
| Mar 11, 2024 | Dec 1, 2023 | -0.22 | -0.39 | -0.17 | -77.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 26, 2024 | Citigroup | main | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2024 | RBC Capital | reit | Outperform | Outperform |
| Jul 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cariboubio.com
News
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy 
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday 
12 Health Care Stocks Moving In Thursday's Intraday Session 
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday 
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's Intraday Session
Nasdaq Falls Over 100 Points; US Crude Inventories Decline 
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday 
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views 
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1
Your note
Sign in to keep a note on CRBU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FISCHESSER RYAN M | Officer | Stock Award(Grant) | Nov 19, 2024 | 118,854 |
| HAURWITZ RACHEL E. PH.D. | Chief Executive Officer | Stock Award(Grant) | Feb 19, 2024 | 3,508,100 |
| KANNER STEVEN B. | Officer | Stock Award(Grant) | Feb 19, 2024 | 387,037 |
| KHAN RUHI AHMAD | Officer | Stock Award(Grant) | Feb 19, 2024 | 33,000 |
| MCCLUNG BARBARA G | Officer | Stock Award(Grant) | Feb 19, 2024 | 409,566 |
| O'BYRNE JASON | Chief Financial Officer | Stock Award(Grant) | Feb 19, 2024 | 59,224 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.99% | 7,233,372 | 12.95M | Sep 29, 2024 |
| Vanguard Group Inc | 5.10% | 4,618,268 | 8.27M | Sep 29, 2024 |
| Bank of America Corporation | 5.05% | 4,570,246 | 8.18M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 4.76% | 4,306,671 | 7.71M | Sep 29, 2024 |
| Kynam Capital Management, LP | 2.60% | 2,356,147 | 4.22M | Sep 29, 2024 |
| Elmwood Wealth Management, Inc. | 2.40% | 2,175,740 | 3.89M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.06% | 2,768,629 | 4.96M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.41% | 2,179,265 | 3.90M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.36% | 1,231,510 | 2.20M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.94% | 846,690 | 1.52M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.89% | 807,142 | 1.44M | Oct 30, 2024 |
| iShares Biotechnology ETF | 0.63% | 572,642 | 1.03M | Oct 30, 2024 |